In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 60 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]	Technology appraisal guidance	TBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]	Technology appraisal guidance	6 May 2027
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]	Technology appraisal guidance	11 February 2026
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]	Technology appraisal guidance	24 February 2027
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)	Health technology evaluation	2 December 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]	Technology appraisal guidance	30 September 2026

Results per page

10
25
50
All